posted
First news in over a month...went from .01 to .15 last time...news isn't as big, but looks like it could run...
Grant Life Sciences Expects to Begin Generating Revenues from Sales of its Rapid Tests for Malaria and Dengue Fever Before Year's End Monday October 24, 9:45 am ET Products are now being manufactured and prepared for shipment to distribution channels that are already in place
MURRAY, Utah--(BUSINESS WIRE)--Oct. 24, 2005-- Grant Life Sciences (OTC Bulletin Board: GLIF - News) announced today that it expects to begin generating revenues this year, possibly within 30 days, on sales of its rapid tests for Malaria and Dengue Fever. These products, along with rapid tests for HIV-1 and HIV-2, were acquired earlier this year from AccuDx Corp., a biotechnology company based in La Jolla, Calif., founded by Ravi Pottahil, Ph.D., one of the world's leading authorities in the field of HIV/AIDS diagnostics and therapeutics. (Dr. Pottahil was the section manager for retroviruses and tumor markers and PCR diagnostics at Hoffman-La Roche from 1985 to 1992, when he co-founded Specialty BioSystems with Specialty Laboratories, one of the largest independent reference laboratories in California. Dr. Pottathil also was an advisor to the World Health Organization's Sexually Transmitted Diseases and Global Vaccination program.) ADVERTISEMENT
Under the agreement with AccuDx, Grant Life Sciences controls the exclusive rights to AccuDx's rapid tests, as well as AccuDx's proprietary colloidal gold reagent. In addition, the agreement established the right for Grant Life Sciences to manufacture these products in AccuDx's 'maquiladora'-modeled contract facility in Tijuana, Mexico, which is registered with the FDA and is ISO 9002-certified. Dr. Pottahil is assisting Grant Life Sciences in expanding its product line to include rapid tests for Hepatitis, Rubella, and other common diseases.
"We are very pleased to report that Grant Life Sciences has been successful in re-establishing the first of several distribution channels previously utilized by AccuDx," said Dr. Hun-Chi Lin, President and Chief Scientist at Grant Life Sciences. "Indeed, we expect to have a working marketing-and-sales mechanism in place prior to the approval necessary for us distribute our blood tests in all of the major foreign markets," added Dr. Lin. "While we are very excited by the opportunity to begin generating revenues soon, this situation also solidly positions Grant Life Sciences for the eventual manufacturing and distribution of our core product, the immunological serum-based test for detecting Cervical Cancer and its precursors," Dr. Lin concluded.
"Having our manufacturing operations in place and our distribution channels ready is the most significant milestone yet for Grant Life Sciences," said Stan Yakatan, Chairman of Grant Life Sciences. "Being able to generate revenues from our products in specialty diagnostic markets outside of the U.S. will provide us with some of the resources necessary to move us forward with the clinical validation of our core product, a rapid test for detecting cervical cancer."
About Grant Life Sciences Inc.
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.
Safe Harbor Statement Under the Private Securities Litigation Act of 1995
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
-------------------------------------------------------------------------------- Contact: Grant Life Sciences, Inc. Don Rutherford, CFO, 949-521-1232
-------------------- I may be wrong, but I don't think so....
IP: Logged |
posted
This is a nice run....took my free shares off the table and will look for a re-entry. This stock moves very quickly and fairly predictable. Will hold the freebies and it falls to .015 to .0175 and then goes from there. Not that I wnat my free shares to go down, but I'm ready to accumulate more when it takes a breather. This news isn't as good as the cervical cancer patent, but we all know in pennyland that almost any news is good news. 44 and strong....
-------------------- I may be wrong, but I don't think so....
IP: Logged |
posted
Actually I think your right... Wilma's got me goin crazy.. we got 100 mph winds at 6am this morning in my house.. sounds like a freight train... families okay though..
posted
If you missed GLIF, you might consider this one -- VTLV. It could give you 100% in 3 weeks thru quarter report play.
****** VTLV: 0.04; S/O -106mm; rev - 5mm/year; book value: 0.183/s; annual growth -25%; expanded business in Asia; patent for new product; postive quarter rep expected in the second week of November; target pps - 0.06 in a month. This stock will shine like PMED, or even better -- since it's not manipulated by the MMs. The pps got a rally every time when a quarter rep was released. Please add your DD on this forum. -- Thanks. ***** I am more confident about VTLV than PMED when I found them based on the following reaseons:
a. VTLV got a rally every 3 months, just before the quarter report was released; next one is due the first week of November; b. The MMs have been accumulating between 0.03 and 0.05; c. The MMs have given out a signal by forming a double bottom recently; this is the best time to get in. d. There are about 12 members of the xxxxxxxxxxxxxx.com who have been playing VTLV; they knew the report releasinbg date, so the volume will increase gradually. e. The fundamentals of the company is better than PMED. f. I am 80% confident that VTLV will reach 0.067 to 0.084 in 3 weeks.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
